



(BMSIC/DRUGS/15-05)

S.N.	Technical Eligibility Criteria as per NIT	Name of Bidder: Nestor Pharmaceuticals Limited Corporate Address:G-1, Ashoka Estate, 24, Barakhamba Road, New Delhi-110001 MU Address: 11, Western Extension Area, Faridabad-121001 "Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-279)"
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	Certificate of Incorporation of the firm submitted (Pg. No.126) MOA and AOA of the company submitted (Pg. No. 71-124)
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Self attested copy of resolution passed at the meeting of the board of Directors of the company on 09/01/2015 resolved that Mr. Manish Kumar, Assistant Manager (Institutional) be and is hereby authorised to represent the company for all tenders documents and sign all relevant documents on behalf of the company. (Page No.172)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	List of quoted item(Products NIT Sr.No.- 6,7,16,17,18,19,22,23,24,36,44,46,56,58,59,63,65,75,80,87,98,106,107,111,112,113,114,159,165,179 and181 (31 Items) submitted in Prescribed format as per annexure iii. NOTE- Pack Size mentioned in the list at NIT Sr. No.106 is 100 ml but as per NIT it should be 200 ml. (Pg. No.5-8).
4	<ul style="list-style-type: none"> • Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	Copy Of Manufacturing Licence in Form-25 & 28 Submitted. M.L No. 224-OSP(H) and 94-B(H) issued date 13/09/1979 renewal in Form -26 having M.L No.94-B(H) and 224-OSP(H) valid upto 31/12/2017, along With quoted product approval for NIT S.No- 6,7,16,17,18,19,22,23,24,36,44,46,56,58,59,63,65,75,80,87,98,106,107,111,112,113,114,159,165,179 and181 submitted. (Pg No 136-172). Details list is in Enclosure
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Details as per enclosure
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self Attested Copy of Non Conviction Certificate Submitted issued by Assistant State Drugs Controller for State Drugs Controller cum Controlling & Licensing Authority, Food & Drugs Administration, Haryana dated 11/11/2014 and 20/08/2013 (Pg. No.53&55) Another Self Attested Copy of Non Conviction Certificate Submitted issued by State Drugs Controller,Controlling & Licensing Authority, Food & Drugs Administration, Haryana dated 06/09/2012 (Page No.51)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule-M/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self Attested copy of GMP Certificate as per revised Schedule - M of Drugs & Cosmetics Rules, 1945 wherein it is stated that this certificate is valid for two years from the date of issue. submitted issued by Deputy State Drugs Controller, Controlling & Licensing Authority, Food & Drugs Administration, Haryana submitted issue dated 07/04/2015 (Page No11) Another Self Attested copy of Site Certificate (As per WHO- GMP Certification Scheme)wherein it is stated that this certificate is valid for two years from the date of issue and it becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP as specified under WHO-GMP Certification Scheme. submitted issued by State Drugs Controller, Controlling & Licensing Authority, Food & Drugs Administration, Haryana submitted issue dated 15/01/2014.(Page No. 10)
9	Self attested copies of Maximum Batch Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self Attested Copy of Prequalified Installed Capacity certificate wherein categorywise(capsules, tablets, dry syrups,injectables,liquid oral and ointments) of drugs on the basis ofNo. of units per shift (8 hours)is mentioned submitted issued by Assistant State Drugs Controller for State Drugs Controller cum Controlling & Licensing Authority, Food & Drugs Administration, Haryana dated 20/12/2013 (Pg. No.47-48)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Affidavit for Non-Blacklisting of the firm & its quoted product by the authorised signatory submitted as per Annexure II of NIT (Pg.No.176-177)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	BG No. 355BGFG15253000L, Rs. 5,00,000/- , Valid upto 30/04/2016, Syndicate Bank Pg. - 4 - 2
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	DD No. 658067, Pg. - 01, Rs. 10,000/-, Andhra Bank
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F. Y. - 11 - 12, Turnover - 164.67 Cr., Pg. - 17 - 18 F. Y. - 12 - 13, Turnover - 102.65 Cr., Pg. - 15 - 16 F. Y. - 13 - 14, Turnover - 113.89 Cr., Pg. - 13 - 14
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A. Y. - 12 - 13, Pg. - 135 A. Y. - 13 - 14, Pg. - 134 A. Y. - 14 - 15, Pg. - 133
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN - AAACN1547, Pg. - 50
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	TIN - 06561300708, Pg. - 45 - 46
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Not submitted in the bid document.

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due diligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepancies is observed, for rectification.

The facts in pages mentioned against the clause No-1 to 10 and 17 of this chart has been verified.

[Handwritten signature]

Nestor Pharmaceuticals Ltd.

PRODUCT LIST APPROVAL & MARKET STANDING STATUS

Sl.no.	NIT S No	Product Name	Product Approval Date/Validity(Pg No.)/S.no.-the below products approval are for the period 1.1.2013-31.12.2017 as per Form 26	Remarks	Market Standing for more than three years(Pg No)/Sl.no	Remarks
1	6	Albendazole Oral Suspension IP 200 mg / 5 ml - 10 ml bottle	25.06.08(167/410)		memo no 1254/dated 16.02.15 (66/26)	pack size not mentioned
2	7	Albendazole Tab. IP 400 mg	08.05.08(165/8)		memo no 1254/dated 16.02.15 (68/01)	
3	16	Amoxicillin Capsule IP 500 mg	25.06.08(164/698)		memo no 1254/dated 16.02.15 (67/21)	
4	17	Amoxicillin Capsule IP 250 mg	25.06.08(164/697)		memo no 1254/dated 16.02.15 (67/20)	
5	18	Amoxicillin Dispersible Tab. IP 125 mg	25.06.08(162/567)		memo no 1254/dated 16.02.15 (67/19)	
6	19	Amoxicillin Oral Suspension IP 125 mg / 5 ml -60ml	25.06.08(163/759)		memo no 1254/dated 16.02.15 (67/22)	pack size not mentioned
7	22	Ampicillin Injection IP 500 mg	25.06.08(161/868)		memo no 1254/dated 16.02.15 (66/29)	
8	23	Antacid Tablets (Tablet Containing : Dried Aluminium Hydroxide Gel - 250 mg, Activated Dimethicon 50 mg	21.04.10(158/13)	Dried aluminium hydroxide gel -200mg insted of 250 mg	memo no 11760/dated 09.09.15 (59/01)	
9	24	Aspirin Tablets IP, 75mg	25.06.08(157/31)		memo no 11760/dated 09.09.15 (58/02)	
10	36	Calcium Tablets (Each tablet Contains : Calcium Carbonate equivalent to 500 mg elemental calcium and Vit D3 - 250 I.U.)	21.10.08&25.06.08(156/584)		memo no 11760/dated 09.09.15 (58/04)	
11	44	Cefixime Tablets IP 100 mg	05.09.11(155/592)		memo no 11760/dated 09.09.15 (58/05)	
12	46	Cefotaxime Sodium Injection IP 1 gm vial	25.06.08(154/903)		(64/06)	
13	56	Ceftriaxone Injection IP 500 mg vial	15.02.12(152/911)	product is in USP specification instead of IP	(64/05)	
14	58	Cetirizine Hydrochloride Tablets IP 10 mg	22.08.08(151/47)		(61/02)	
15	59	Cetirizine Syrup IP, 5mg/5ml, 30ml	22.08.08(150/418)	pack size not mentioned	memo no 11760/dated 09.09.15 (58/06)	pack size not mentioned
16	63	Chlorpheniramine Tablets IP 4 mg	25.06.08(159/55)		memo no 1254/dated 16.02.15 (67/14)	

Sl.no.	NIT S No	Product Name	Product Approval Date/Validity(Pg No.)/S.no.-the below products approval are for the period 1.1.2013-31.12.2017 as per Form 26	Remarks	Market Standing for more than three years(Pg No)/Sl.no	Remarks
17	65	Ciprofloxacin Hydrochloride Tablets IP 250 mg	25.06.08(148/67)		memo no 1254/dated 16.02.15 (68/05)	
18	75	Dexamethasone Inj.IP, 4mg/ml, 2ml vial	25.06.08(147/950)		memo no 1254/dated 16.02.15 (66/32)	pack size not mentioned
19	80	Diclofenac Sodium Gastro-Resistant Tablets IP, 50mg	25.06.08(146/93)	Gastro resistant is not specified	memo no 9020/dated 11.11.14 (61/03)	Gastro resistant is not specified
20	87	Doxycycline Capsules IP 100 mg	25.06.08(145/719)		memo no 9020/dated 11.11.14 (61/01)	
21	98	Gentamicin Injection IP 40 mg / ml - 2 ml vial	25.06.08(144/978)		memo no 1254/dated 16.02.15 (66/33)	pack size not mentioned
22	106	Iron and Folic Acid Syrup IP (Each 5 ml contains Ferrous sulphate equivalent to 100 mg of elemental ferrous iron & 0.5 mg of Folic Acid. (To be labelled as per sch. V)-200ml)	20.502013(143/01)	pack size of 200ml not mentioned	memo no 1254/dated 16.02.15 (66/28)	pack size not mentioned
23	107	Iron and Folic Acid Tab. (Each Tablet contains ferrous sulphate equivalent to 20 mg of ferrous elemental Iron and 100 µg of Folic Acid (to be labelled as per Schedule V))	25.08.11(141/646)		memo no 1254/dated 16.02.15 (67/17)	
24	111	Isosorbide Dinitrate Tablets IP, 10mg	25.06.08(140/185)		memo no 11760/dated 09.09.15 (58/08)	
25	112	Isosorbide Dinitrate Tablets IP, 5mg	25.06.08(140/184)		memo no 11760/dated 09.09.15 (58/07)	
26	113	Isosorbide Mononitrate Tablets IP, 10mg	25.06.08(140/186)	i)product is in BP specification instead of IP	memo no 11760/dated 09.09.15 (58/09)	
27	114	Isosorbide Mononitrate Tablets IP, 20mg	25.06.08(140/187)	i)product is in BP specification instead of IP	memo no 11760/dated 09.09.15 (58/10)	
28	159	Paracetamol Syrup IP 125 mg / 5 ml - 60 ml	25.06.08(139/466)	pack size not mentioned	memo no 1254/dated 16.02.15 (66/27)	pack size not mentioned
29	165	Piperacillin & Tazobactam for Injection (Piperacillin 4 gm & Tazobactam 500 mg) - 4.5 gm vial	20.04.12(138/1050)		memo no 11760/dated 09.09.15 (58/12)	
30	179	Ranitidine Tablets IP 150 mg	25.06.08& 26.11.09(137/313)		memo no 11760/dated 09.09.15 (57/16)	
31	181	Salbutamol Tablets IP 4 mg	25.06.08(136/319)		memo no 11760/dated 09.09.15(57/17)	